In a lung adenocarcinoma simultaneously harboring multiple heterogeneous clones of EGFR mutation and K-ras mutation, the effect of EGFR TKIs may be limited only to the parts carrying EGFR mutation but not to the other parts carrying K-ras mutations [36,37]. The gene discussed is KRAS; the disease is lung adenocarcinoma.